Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.95 |
|---|---|
| High | 2.98 |
| Low | 2.83 |
| Bid | 2.91 |
| Offer | 2.92 |
| Previous close | 3.04 |
| Average volume | 11.12m |
|---|---|
| Shares outstanding | 308.10m |
| Free float | 301.15m |
| P/E (TTM) | 157.17 |
| Market cap | 935.08m USD |
| EPS (TTM) | 0.0193 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 15:12 GMT.
More ▼
- MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
- MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
- MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
- MannKind Provides Business Updates and 2026 Growth Drivers
- MannKind Shares FUROSCIX® Business Updates
- MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
- MannKind to Present at the Jefferies Global Healthcare Conference
- MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
More ▼
